Nonacidic Chemotype Possessing N-Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists

被引：12
|
作者：
Teno, Naoki [1 ,2 ]
Yamashita, Yukiko [3 ]
Ig, Yusuke [3 ]
Fujimori, Ko [4 ]
Une, Mizuho [1 ,3 ]
Nishimaki-Mogami, Tomoko [5 ]
Hiramoto, Takie [1 ]
Gohda, Keigo [6 ]
机构：
[1] Hiroshima Int Univ, Grad Sch Pharmaceut Sci, 5-1-1 Hirokoshingai, Kure, Hiroshima 7370112, Japan
[2] Hiroshima Int Univ, Fac Clin Nutr, 5-1-1 Hirokoshingai, Kure, Hiroshima 7370112, Japan
[3] Hiroshima Int Univ, Fac Pharmaceut Sci, 5-1-1 Hirokoshingai, Kure, Hiroshima 7370112, Japan
[4] Osaka Univ Pharmaceut Sci, Fac Pharmaceut Sci, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan
[5] Natl Inst Hlth Sci, Setagaya Ku, Kamiyoga 1-18-1, Tokyo 1588501, Japan
[6] Kansai CAMM Kansai, Comp Aided Mol Modeling Res Ctr, 3-32-302 Tsuto, Nishinomiya, Hyogo 6638241, Japan
来源：
ACS MEDICINAL CHEMISTRY LETTERS | 2018年 / 9卷 / 02期
基金：
日本学术振兴会;
关键词：
FXR antagonists; benzimidazole scaffold; N-acylated piperidine; triglyceride accumulation; ORPHAN NUCLEAR RECEPTOR; BILE-ACID; ADIPOCYTE DIFFERENTIATION; IDENTIFICATION; OPTIMIZATION; DISCOVERY; LIGANDS; HOMEOSTASIS; DERIVATIVES; MODULATORS;
D O I：
10.1021/acsmedchemlett.7b00363
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Famesoid X receptor (FXR) plays a major role in the control of cholesterol metabolism. Antagonizing transcriptional activity of FXR is an effective means to treat the relevant metabolic syndrome. Some of antagonists so far have the charged functions; however, they may negatively affect the pharmacokinetics. We describe herein a structure activity relationship (SAR) exploration of nonacidic FXR antagonist 6 focusing on two regions in the structure and biological evaluation of nonacidic 10 with the characteristic N-acylated piperidine group obtained from SAR studies. As the robust affinity to FXR is feasible with our nonacidic analogue, 10 is among the most promising candidates for in vivo testing.
引用
收藏
页码：78 / 83
页数：6
相关论文
共 35 条
  • [21] N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR)
    Masuda, Arisa
    Gohda, Keigo
    Iguchi, Yusuke
    Fujimori, Ko
    Yamashita, Yukiko
    Oda, Keisuke
    Une, Mizuho
    Teno, Naoki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (14)
  • [22] Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists
    Song, Kebiao
    Xu, Xing
    Liu, Peng
    Chen, Lili
    Shen, Xu
    Liu, Junhua
    Hu, Lihong
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (19) : 6427 - 6436
  • [23] Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands
    Festa, Carmen
    Renga, Barbara
    D'Amore, Claudio
    Sepe, Valentina
    Finamore, Claudia
    De Marino, Simona
    Carino, Adriana
    Cipriani, Sabrina
    Monti, Maria Chiara
    Zampella, Angela
    Fiorucci, Stefano
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (20) : 8477 - 8495
  • [24] Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis
    Jiang, Li-Juan
    Bhattacharya, Dipankar
    Chou, Hsin I.
    Chau, Mary D.
    Li, Yang
    Or, Yat Sun
    Friedman, Scott L.
    HEPATOLOGY, 2017, 66 : 90A - 90A
  • [25] 4-(TETRAZOLYLALKYL)PIPERIDINE-2-CARBOXYLIC ACIDS - POTENT AND SELECTIVE N-METHYL-D-ASPARTIC ACID RECEPTOR ANTAGONISTS WITH A SHORT DURATION OF ACTION
    ORNSTEIN, PL
    SCHOEPP, DD
    ARNOLD, MB
    LEANDER, JD
    LODGE, D
    PASCHAL, JW
    ELZEY, T
    JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (01) : 90 - 97
  • [26] Synthesis and Biological Evaluation of N-(5-(2,5-dimethyl-phenoxy)-2,2dimethylpentyl)-benzamide Derivatives as Novel Farnesoid X Receptor (FXR) Antagonist
    Nian, Siyun
    Yu, Zhenpeng
    Tan, Xiangduan
    Gan, Xia
    Huang, Mohan
    Zhou, Yihuan
    Wang, Guoping
    LETTERS IN DRUG DESIGN & DISCOVERY, 2018, 15 (09) : 923 - 936
  • [27] The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRα/β-dual agonist)
    Takamatsu, Kayo
    Takano, Atsushi
    Yakushiji, Nobumasa
    Morohashi, Kazunori
    Morishita, Kenichi
    Matsuura, Nobuyasu
    Makishima, Makoto
    Tai, Akihiro
    Sasaki, Kenji
    Kakuta, Hiroki
    CHEMMEDCHEM, 2008, 3 (05) : 780 - 787
  • [28] N-Substituted Phenoxazine and Acridone Derivatives: Structure-Activity Relationships of Potent P2X4 Receptor Antagonists
    Hernandez-Olmos, Victor
    Abdelrahman, Aliaa
    El-Tayeb, Ali
    Freudendahl, Diana
    Weinhausen, Stephanie
    Mueller, Christa E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 9576 - 9588
  • [29] Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor
    Xu, Xing
    Xu, Xin
    Liu, Peng
    Zhu, Zhi-yuan
    Chen, Jing
    Fu, Hai-an
    Chen, Li-li
    Hu, Li-hong
    Shen, Xu
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (32) : 19888 - 19899
  • [30] (E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells
    Stefela, Alzbeta
    Kaspar, Miroslav
    Drastik, Martin
    Kronenberger, Thales
    Micuda, Stanislav
    Dracinsky, Martin
    Klepetarova, Blanka
    Kudova, Eva
    Pavek, Petr
    FRONTIERS IN PHARMACOLOGY, 2021, 12
1234